AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study

被引：42
|
作者：
Fong, P. C.
Boss, D. S.
Carden, C. P.
Roelvink, M.
De Greve, J.
Gourley, C. M.
Carmichael, J.
De Bono, J. S.
Schellens, J. H.
Kaye, S. B.
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] UZ Brussel, Ctr Oncol, Brussels, Belgium
[4] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[5] Kudos Pharmaceut, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5510
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.
    Stecca, Carlos
    Vilbert, Maysa
    Michelon, Isabella
    Castro, Caio
    Dacoregio, Maria Inez
    Fin, Fabio
    Tsunoda, Audrey Tieko
    De Melo, Andreia Cristina
    Da Costa, Alexandre Andre B. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Phase 0 pharmacodynamic, pharmacokinetic study of ABT-888, an inhibitor of poly (ADP-ribose) polymerase (PARP), in patients with advanced malignancies
    Kummar, S.
    Gutierrez, M.
    Kinders, R.
    Rubinstein, L.
    Parchment, R. E.
    Phillips, L.
    Ji, J.
    Chen, A.
    Homeffer, Y.
    Juwara, L.
    Yancey, M.
    Murgo, A. J.
    Collins, J. M.
    Tomaszewski, J. E.
    Doroshow, J. H.
    ANNALS OF ONCOLOGY, 2008, 19 : 20 - 20
  • [33] Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and recurrent ovarian cancer
    Li, N.
    Bu, H.
    Liu, J.
    Zhu, J.
    Zhou, Q.
    Wang, L.
    Yin, R.
    Wu, X.
    Yao, S.
    Gu, K.
    Zhang, H.
    Li, G.
    Pan, H.
    Wu, Q.
    An, R.
    Yang, X.
    Zhu, Y.
    Wan, X.
    Duan, W.
    Xiong, J.
    Wang, Y.
    Wang, Q.
    Zou, J.
    Wu, L. Y.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 159 - 159
  • [34] Associations with response to poly(ADP-ribose) polymerase (PARP) inhibitors in patients with BRCA mutated metastatic breast cancer: Results of a meta-regression analysis
    Desnoyers, Alexandra
    Wilson, Brooke E.
    Nadler, Michelle B.
    Amir, Eitan
    CANCER RESEARCH, 2021, 81 (04)
  • [35] Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide.
    Plummer, R
    Middleton, M
    Wilson, R
    Evans, J
    Jones, C
    Olson, A
    Boddy, A
    Curtin, N
    Kaufman, R
    Harris, A
    Johnston, P
    Newell, H
    Robson, L
    Dewji, R
    Calvert, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9099S - 9099S
  • [36] DNA repair protein expression and response of homologous recombination deficient ovarian cancer to the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in the ARIEL2 Part 1 study
    Hendrickson, Andrea E. Wahner
    Lin, Kevin K.
    Visscher, Daniel W.
    Hurley, Rachel M.
    Raponi, Mitch
    Harding, Thomas C.
    Murphy, Linda M.
    Wagner, Jill M.
    Giordano, Heidi
    McNeish, Iain
    Swisher, Elizabeth M.
    Kaufmann, Scott
    CANCER RESEARCH, 2017, 77
  • [37] First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
    Schelman, W. R.
    Sandhu, S. K.
    Garcia, V. Moreno
    Wilding, G.
    Sun, L.
    Toniatti, C.
    Stroh, M.
    Kreischer, N.
    Carpenter, C. L.
    Molife, L. R.
    Kaye, S. B.
    De Bono, J. S.
    Wenham, R. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells
    Wu, Xiaochen
    Li, Qiqi
    Zhang, Fan
    Wang, Lijun
    Wang, Jun
    Fan, Junting
    Di, Guohu
    Guo, Chuanlong
    FOOD AND CHEMICAL TOXICOLOGY, 2021, 147
  • [39] Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    Audeh, M. William
    Carmichael, James
    Penson, Richard T.
    Friedlander, Michael
    Powell, Bethan
    Bell-McGuinn, Katherine M.
    Scott, Clare
    Weitzel, Jeffrey N.
    Oaknin, Ana
    Loman, Niklas
    Lu, Karen
    Schmutzler, Rita K.
    Matulonis, Ursula
    Wickens, Mark
    Tutt, Andrew
    LANCET, 2010, 376 (9737): : 245 - 251
  • [40] Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
    Drew, Y.
    Ledermann, J. A.
    Jones, A.
    Hall, G.
    Jayson, G. C.
    Highley, M.
    Rea, D.
    Glasspool, R. M.
    Halford, S. E. R.
    Crosswell, G.
    Colebrook, S.
    Boddy, A. V.
    Curtin, N. J.
    Plummer, E. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345